<?xml version="1.0" encoding="UTF-8"?>
<p id="Par11">Recently, hydroxychloroquine and chloroquine had been reported to be of importance in relevance to COVID-19. These are oral prescription drugs that have been used for the treatment of malaria and certain inflammatory conditions like rheumatoid arthritis, systemic lupus erythematosus, and porphyria cutanea tarda. Both of these drugs have in vitro activity against SARS-CoV, SARS-CoV-2, and other coronaviruses, with hydroxychloroquine having relatively higher potency against SARS-CoV-2 [
 <xref ref-type="bibr" rid="CR51">51</xref>, 
 <xref ref-type="bibr" rid="CR53">53</xref>, 
 <xref ref-type="bibr" rid="CR54">54</xref>]. A study in China reported that chloroquine treatment of COVID-19 patients had the clinical and virologic benefit and they recommended this as an antiviral drug or the treatment of COVID-19 in China [
 <xref ref-type="bibr" rid="CR55">55</xref>]. In the USA, several clinical trials of hydroxychloroquine for prophylaxis or treatment of SARS-CoV-2 infection are going on. Although its temporary use on patients in hospitals during the COVID-19 pandemic has been authorized by the FDA, still it has not been certified as safe and successful for treating or preventing COVID-19.
</p>
